BridgeBio Oncology Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview

Reuters

Feb 28

BridgeBio Oncology <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc <bbot.oq> expected to post a loss of 52 cents a share - Earnings Preview </bbot.oq>

BridgeBio Oncology Therapeutics Inc BBOT.OQ BBOT.O is expected to report resultson March 3 (estimated) for the period ending December 31 2025
LSEG's mean analyst estimate for BridgeBio Oncology Therapeutics Inc is for a loss of 52 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for BridgeBio Oncology Therapeutics Inc is $23.50, about 129.3% above its last closing price of $10.25

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER ENDING	STARMINESMARTESTIMATE®	LSEG IBES ESTIMATE	ACTUAL	BEAT, MET, MISSED	SURPRISE %
Sep. 30 2025	-0.46	-0.39	-1.03	Missed	-164.2
2025

This summary was machine generated February 27 at 21:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2614867572"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614867572\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614867572?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-28 05:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614867572","market":"us","top_or_hot":-1,"title":"BridgeBio Oncology Therapeutics Inc  expected to post a loss of 52 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BridgeBio Oncology <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <bbot.oq> expected to post a loss of 52 cents a share - Earnings Preview </bbot.oq></title></head><body><ul><li><p>BridgeBio Oncology Therapeutics Inc <span>BBOT.OQ</span> <span>BBOT.O</span> is expected to  report resultson March 3 (estimated) for the period ending December 31 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for BridgeBio Oncology Therapeutics Inc is for a loss of 52 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for BridgeBio Oncology Therapeutics Inc is $23.50, about 129.3% above its last closing price of $10.25</p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Sep. 30 2025</p></td><td><p>-0.46</p></td><td><p>-0.39</p></td><td><p>-1.03</p></td><td><p>Missed</p></td><td><p>-164.2</p></td></tr><tr><td><p> 2025</p></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td><p></p></td></tr><tr><td><p></p></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td><p></p></td></tr></tbody></table><p>This summary was machine generated February 27 at 21:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BridgeBio Oncology Therapeutics Inc  expected to post a loss of 52 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBridgeBio Oncology Therapeutics Inc  expected to post a loss of 52 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-28 05:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BridgeBio Oncology <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <bbot.oq> expected to post a loss of 52 cents a share - Earnings Preview </bbot.oq></title></head><body><ul><li><p>BridgeBio Oncology Therapeutics Inc <span>BBOT.OQ</span> <span>BBOT.O</span> is expected to  report resultson March 3 (estimated) for the period ending December 31 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for BridgeBio Oncology Therapeutics Inc is for a loss of 52 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for BridgeBio Oncology Therapeutics Inc is $23.50, about 129.3% above its last closing price of $10.25</p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Sep. 30 2025</p></td><td><p>-0.46</p></td><td><p>-0.39</p></td><td><p>-1.03</p></td><td><p>Missed</p></td><td><p>-164.2</p></td></tr><tr><td><p> 2025</p></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td><p></p></td></tr><tr><td><p></p></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td><p></p></td></tr></tbody></table><p>This summary was machine generated February 27 at 21:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL8N3ZN2RW:1","article_id":"2614867572","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614867572","pubTimestamp":1772227926,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BridgeBio Oncology Therapeutics Inc  expected to post a loss of52cents a share - Earnings Preview BridgeBio Oncology Therapeutics Inc BBOT.OQ BBOT.O is expected to  report resultson March 3 (estimated","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BBOT":"BridgeBio Oncology Therapeutics, Inc","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","BBIO":"BridgeBio Pharma, Inc."},"translate_title":"BridgeBio Oncology Therapeutics Inc预计每股亏损52美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":0.9,"BBOT":0.9},"content_text":"BridgeBio Oncology Therapeutics Inc  expected to post a loss of 52 cents a share - Earnings Preview BridgeBio Oncology Therapeutics Inc BBOT.OQ BBOT.O is expected to  report resultson March 3 (estimated) for the period ending December 31 2025LSEG's mean analyst estimate for BridgeBio Oncology Therapeutics Inc is for a loss of 52 cents per share. The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for BridgeBio Oncology Therapeutics Inc is $23.50, about 129.3% above its last closing price of $10.25Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATE ACTUALBEAT, MET, MISSEDSURPRISE %Sep. 30 2025-0.46-0.39-1.03Missed-164.2 2025This summary was machine generated February 27 at 21:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}